Compare GSK plc (GSK) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Motorola Solutions Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Motorola Solutions Inc trades at $443.51 (market cap $74.00B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Motorola Solutions Inc for 100 Days on average.
| GSK | MSI | |
|---|---|---|
Market Cap | $91.88B | $74.00B |
Volume | 7,730,529 | 722,147 |
Sector | Health | Technology |
52-Week High | $61.18 | $491.24 |
52-Week Low | $43.24 | $363.83 |
Typical Hold Time | 93 Days | 100 Days |
Enterprise Value | $111.88B | $82.90B |
Dividend Yield | 3.9% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
MSI trades at $444.18, down 0.96% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth has been steady, reaching $11.68 billion in 2025, and the firm recently announced a $2 billion share repurchase increase and a $139 million public safety contract in Louisiana.
The outlook remains positive with a consensus price target of $525.86, implying 18% upside, supported by a 70.59% buy rating from analysts. Risks include elevated valuation multiples, such as a P/E of 35.23, and significant investing cash outflows for acquisitions, which pressured net cash flow to -$937 million in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
